Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Checkpoint Inhibitors in Skin Cancer: Guidelines, Neoadjuvant Use, and Toxicity Management
Description
The speaker describes how a personal patient case shaped his career and emphasizes that the talk is not about dermatologists prescribing immunotherapy themselves, but about understanding checkpoint inhibitor care pathways, guidelines, and toxicity management so patients are referred appropriately and managed proactively. He reviews the basics of immune oncology, explaining that checkpoint inhibitors work by enhancing immune recognition of cancer, with CTLA-4 acting in the priming phase, PD-1/PD-L1 in the effector phase, and LAG-3 as a newer target; he also notes emerging targets such as TIM3, TIGIT, and BTLA. The talk focuses on skin cancer uses approved by the FDA and highlighted in NCCN guidance, including melanoma, Merkel cell carcinoma, squamous cell carcinoma, and basal cell carcinoma. For basal cell carcinoma, he notes checkpoint inhibitors can be used similarly to hedgehog inhibitors in locally advanced or metastatic disease, especially if hedgehog therapy is not suitable or fails. For cutaneous squamous cell carcinoma, he highlights new evidence supporting adjuvant checkpoint inhibition in very high-risk disease and the growing neoadjuvant role, citing major trials with meaningful disease-free survival and pathologic complete response benefits. Merkel cell carcinoma is presented as an especially aggressive disease where checkpoint inhibitors are important in advanced settings and increasingly in the neoadjuvant space. For melanoma, he stresses the debated but important adjuvant use in stage 2B/2C disease and neoadjuvant use in stage 3 disease. He also underscores that dermatologists often encounter the skin toxicities first, and common immune-related adverse events include dermatitis, colitis, fatigue, and endocrine toxicities, some of which may be irreversible. Overall, the key message is to understand guidelines, recognize when checkpoint inhibitors are appropriate, coordinate multidisciplinary care, and be prepared to manage or triage immune-related toxicities.
View moreConclusions
- Checkpoint inhibitors have become a central cancer treatment strategy by amplifying anti-tumor immunity, with CTLA-4 acting early in T-cell priming, PD-1/PD-L1 and LAG-3 acting later in the effector phase, and additional targets likely to expand the field further.
- For dermatologic cancers, NCCN guidelines now place checkpoint inhibitors into routine decision pathways for advanced basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.
- Multidisciplinary care is essential because dermatologists, surgeons, oncologists, and radiation oncologists must coordinate referral, sequencing, and follow-up rather than working in isolated treatment silos.
- Neoadjuvant checkpoint blockade is increasingly important in skin cancer, particularly for resectable cutaneous squamous cell carcinoma, Merkel cell carcinoma, and stage III melanoma.
- Adjuvant checkpoint inhibition can reduce recurrence risk in high-risk disease, especially in stage IIB/IIC melanoma and very-high-risk cutaneous squamous cell carcinoma.
- The benefits of checkpoint inhibitors must be balanced against clinically meaningful toxicities, especially immune-related skin, endocrine, and other organ toxicities that may be severe or irreversible.
- In stage IIB/IIC melanoma, pembrolizumab improves recurrence-free and distant metastasis-free survival, but the absolute benefit must be weighed against endocrine and other immune-related adverse events.
- In high-risk cutaneous squamous cell carcinoma, neoadjuvant cemiplimab produces substantial pathologic complete response rates and supports preoperative systemic therapy as a valuable option.
- Merkel cell carcinoma remains highly aggressive, but checkpoint inhibitors now have a growing role across neoadjuvant, adjuvant, and metastatic settings.
- Overall, the presentation argues that dermatologists need to understand checkpoint inhibitor indications and toxicity management so they can guide patients to the right treatment at the right time.
- Michot JM, et al. Eur J Cancer. 2016;54:139.
- Robert C. ASCO 2017 education session on checkpoint inhibitor immunotherapy.
- A new member of the immunoglobulin superfamily—CTLA-4. Nature.#10.1038/328267a0
- LAG-3 as the third checkpoint inhibitor. Nature Immunology. 2023.#10.1038/s41590-023-01569-z
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.#10.1038/nrc3239
- Xu, Huang, Li, and Ma. Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology. Cancer Letters.#10.1016/j.canlet.2026.218359
- Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2022;387:1557-1568.#10.1056/nejmoa2209813
- Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718-1729.#10.1016/s0140-6736(22)00562-1